• Français


View Profile











CHU Pontchaillou – 2 rue Henri Le Guilloux – 35033 Rennes Cedex




Radiochemistry; Organic and Coordination Chemistry; Nanoparticle formulation;

Radiopharmaceuticals; Nuclear Medicine; Liver cancers.

Research topics and scientific objectives

Research interests include bioinorganic and radiopharmaceutical chemistry, and the development of radiopharmaceuticals and nanoparticles containing radioisotopes for radionuclide therapy and molecular imaging.

Education and main positions held

2019: Habilitation à Diriger les Recherches (D.Sc.) in Medicine from the University of Rennes 1.

2003: Ph.D. in Chemistry from the University of Rennes 1.

2003: Dottorato di Ricerca in Scienze Chimiche from the University of Ferrara (Italy).

2000: Engineer from the Ecole Nationale Supérieure de Chimie de Rennes (ENSCR).

2000: DEA (Master degree) in Fine Chemistry – Syntheses and Production; University of Rennes 1/ENSCR.

Current position:

Radiopharmaceutical Scientist in the Pharmacy Department of the Comprehensive Cancer Centre Eugène Marquis, in Rennes, France

Current projects

Current projects include:

1) Development of 188Re- and 90Y-labelled Lipiodol (radioembolisation of liver cancers).

2) Development of an HCC-specific peptide, its radiolabelling, and its use for targeting radiolabelled nanoparticles.

3) Study of tumor and microenvironmental responses after radionuclide therapy.

Selected publications

– N. Lepareur, F. Lacœuille, C. Bouvry, F. Hindré, E. Garcion, M. Chérel, N. Noiret, E. Garin, F. F. (Russ) Knapp Jr, Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives, Frontiers in Medicine – Nuclear Medicine, 2019, doi: 10.3389/fmed.2019.00132.

– K. Delaunay, J. Edeline, Y. Rolland, N. Lepareur, S. Laffont, X. Palard, C. Bouvry, S. Le Sourd, M. Pracht, V. Ardisson, N. Noiret, É. Bellissant, E. Garin, Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization, Eur. J. Nucl. Med. Mol. Imaging, 2019, 46, 1506-1517.

– M. Le Fur, M. Beyler, E. Molnar, O. Fougere, D. Esteban-Gómez, G. Tircsó, C. Platas-Iglesias, N. Lepareur, O. Rousseaux, R. Tripier, Role of the capping bond effect on pyclen natY3+/90Y3+ chelates: full control of the regiospecific N-functionalisation makes the difference, Chem. Commun., 2017, 53, 9534-9537.

– D. Séhédic, I. Chourpa, C. Tétaud, A. Griveau, C. Loussouarn, S. Avril, C. Legendre, N. Lepareur, D. Wion, F. Hindré, F. Davodeau, E. Garcion, Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma, Theranostics, 2017, 7, 4517-4536.

– N. Lepareur, L. Leal E Costa, M. Bocqué, C. Blondelle, C. Ruello, M. Desjulets, N. Noiret, S. Cammas-Marion, Development of biocompatible and functional polymeric nanoparticles for site-specific delivery of radionuclides, Frontiers in Medicine – Nuclear Medicine, 2015, 2:63. doi: 10.3389/fmed.2015.00063.